Hikma PharmaceuticalsHKMPY 87 Forward Dividend Yield % is 4.07% as of Jun. 29, 2026. GuruFocus rates HKMPY with a GF Score™ of 87/100 and a GF Value™ of $56.71 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 505 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 78.81% on this metric.
As of today (2026-06-29), the Forward Annual Dividend Yield of Hikma Pharmaceuticals is 4.07%.
As of today (2026-06-29), the Trailing Annual Dividend Yield of Hikma Pharmaceuticals is 4.07%.
HKMPY's Forward Dividend Yield % is ranked better than 78.81% of 505
companies
in the Drug Manufacturers industry
Industry Median: 2.08
vs HKMPY: 4.07
During the past 12 months, Hikma Pharmaceuticals's average Dividends Per Share Growth Rate was 1.00% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 13.20% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 14.00% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 12.80% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Hikma Pharmaceuticals was 38.40% per year. The lowest was 8.90% per year. And the median was 15.70% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Hikma Pharmaceuticals Forward Dividend Yield % Related Terms
HKMPY vs ZTS, UTHR, VTRS: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's Forward Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Hikma Pharmaceuticals Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
USD 0.960000
2026-03-20
2026-03-20
2026-05-11
Cash Dividend
semi-annually
USD:USD 1.000000
USD 0.720000
2025-08-18
2025-08-18
2025-09-29
Cash Dividend
semi-annually
USD:USD 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Hikma Pharmaceuticals's Forward Annual Dividend Yield (%) for Today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 4.07% mean?
Hikma Pharmaceuticals (HKMPY) has a Forward Dividend Yield % of 4.07% as of Jun. 29, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Hikma Pharmaceuticals and its competitors. According to the industry distribution chart, Hikma Pharmaceuticals ranks #107 out of 505 companies in the Drug Manufacturers industry, placing it in the top 21.2%.
Is Hikma Pharmaceuticals' Forward Dividend Yield % too high?
Hikma Pharmaceuticals' current Forward Dividend Yield % is 4.07%. The Drug Manufacturers industry median Forward Dividend Yield % is 2.08. Hikma Pharmaceuticals' value of 4.07% is 95.7% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #107 out of 505 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hikma Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #107 out of 505 companies for Forward Dividend Yield %. This places Hikma Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. The industry median Forward Dividend Yield % is 2.08. Hikma Pharmaceuticals' value of 4.07% is 95.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.08, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current Forward Dividend Yield % of 4.07% is 95.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current Forward Dividend Yield % is 4.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPY) is currently considered Modestly Undervalued. The stock's GF Value™ is $56.71, compared to a current price of $41.23 — trading 27.3% below its estimated fair value. The current Forward Dividend Yield % is 4.07% and 95.7% above the Drug Manufacturers industry median of 2.08. Hikma Pharmaceuticals' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPY), the current Forward Dividend Yield % is 4.07% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPY) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $41.23 is trading 27.3% below its estimated GF Value™ of $56.71.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPY:
Forward Dividend Yield %: 4.07%
GF Value™: $56.71 vs. price of $41.23 (27.3% below fair value)
Industry Position: 95.7% above the Drug Manufacturers median (#107 of 505)
No single metric tells the full story. See the HKMPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
87GF Score
Get the complete analysis for HKMPY
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPY has been successfully added to your 